| TG THERAPEUTICS DL -,001 |
| USA |
| Gesundheit |
| US88322Q1085 / A1JXW7 |
| NKB2 (Frankfurt) / TGTX (NASDAQ) |
| FRA:NKB2, ETR:NKB2, NKB2:GR, NASDAQ:TGTX |
| - |
| http://www.tgtherapeutics.. |
|
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing novel therapies for B‑cell mediated diseases. The company’s primary commercial product is BRIUMVI, an anti‑CD20 monoclonal antibody approv..
>Volltext.. |
| 7110.59 Mio. EUR |
| 7317.56 Mio. EUR |
| 607.71 Mio. EUR |
| 131.08 Mio. EUR |
| 400.8 Mio. EUR |
| 2.76 EUR |
| 653.88 Mio. EUR |
| 383.71 Mio. EUR |
| -12.11 Mio. EUR |
| 2.75 |
| 69.72% |
| 1004.76% |
| - |
| - |
| - |
| - |
| TG THERAPEUTICS, TG THERAPEUTIC, TG THERA |
| 03.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|